311 related articles for article (PubMed ID: 18825743)
1. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
[TBL] [Abstract][Full Text] [Related]
3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
4. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
6. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
Perret R; Ronchese F
Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
[TBL] [Abstract][Full Text] [Related]
7. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
8. Effector T-cell differentiation during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of CD8(+) T cells.
Keppler SJ; Theil K; Vucikuja S; Aichele P
Eur J Immunol; 2009 Jul; 39(7):1774-83. PubMed ID: 19548244
[TBL] [Abstract][Full Text] [Related]
9. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A
Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805
[TBL] [Abstract][Full Text] [Related]
10. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
13. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
15. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
16. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo.
Blattman JN; Grayson JM; Wherry EJ; Kaech SM; Smith KA; Ahmed R
Nat Med; 2003 May; 9(5):540-7. PubMed ID: 12692546
[TBL] [Abstract][Full Text] [Related]
18. Type I IFN substitutes for T cell help during viral infections.
Wiesel M; Kratky W; Oxenius A
J Immunol; 2011 Jan; 186(2):754-63. PubMed ID: 21160039
[TBL] [Abstract][Full Text] [Related]
19. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
20. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.
Rodrigues L; Nandakumar S; Bonorino C; Rouse BT; Kumaraguru U
Mol Immunol; 2009 Apr; 46(7):1494-504. PubMed ID: 19233474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]